Wald DS, et al. Am J Med 2009;122:290-300. Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:290-300.

Slides:



Advertisements
Similar presentations
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.
Advertisements

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
CHARM Program: 3 Component trials comparing candesartan with placebo.
חזק בהגנה לבבית Valsartan in Heart Failure
NHANES III Prevalence of Hypertension* According to BMI
Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.
Nursing 210 Advanced Cardiac UNIT 2 Laurie Brown RN, MSN, MPA-HA, CCRN.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.
Pharmacological Treatment of Hypertension Update 2012.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
It’s not just blood pressure…it’s poor impulse control! dP/dt – Change in pressure per Unit of time.
Study flow diagram BB=blockers; HTN=hypertension; RCT=randomized controlled trial Bangalore S. et al. Am J Cardiol. 2007;100:
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Initial Combination Treatment in Hypertension: Who Are the Candidates George Bakris, MD, F.A.S.H., F.A.S.N. Professor of Medicine Director, Hypertensive.
Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
Shalev V, et al. Arch Intern Med 2009; 169:
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:
OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.
Risk Factor Modification in CCR. How does CR work?
Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.
Journal Club Mallory McClester, PGY-4 August 16, 2013.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;
Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med.
What should the Systolic BP treatment goal be in patients with CKD?
Copyright © 2005 American Medical Association. All rights reserved.
Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
Neal B, et al. Diabetes Care 2015;38:403–411
Risk factor thresholds: their existence under scrutiny
Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic
Mean BP from initial visit to four years
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.
Why double blind, controlled randomized trials?
End point Net change with soy supplements vs control (95% CI) p
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Solving Equations 3x+7 –7 13 –7 =.
Volume 72, Issue 12, Pages (December 2007)
Baseline Characteristics, Blood Pressures, and Laboratory Values
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Study Identification and Selection Process
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Álvares et al. Am J Nephrol 2017;45: (DOI: / )
Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.
Presentation transcript:

Wald DS, et al. Am J Med 2009;122:

Details of the 42 Trials Included in the Meta-analysis - Part I Wald DS, et al. Am J Med 2009;122:

Details of the 42 Trials Included in the Meta-analysis - Part II Wald DS, et al. Am J Med 2009;122:

Details of the 42 Trials Included in the Meta-analysis - Part III Wald DS, et al. Am J Med 2009;122:

Details of the 42 Trials Included in the Meta-analysis - Part IV Wald DS, et al. Am J Med 2009;122:

Mean placebo-subtracted systolic blood pressure reduction from a meta-analysis of 42 randomized factorial trials of thiazides, beta-blockers, ACE inhibitors, or calcium channel blockers Wald DS, et al. Am J Med 2009;122:

Ratio of observed to expected incremental blood pressure-lowering effects of adding a drug or doubling the dose according to the class of drug Wald DS, et al. Am J Med 2009;122:

Comparison of observed placebo-subtracted reduction in systolic blood pressure of 2 drugs together against the expected effect of 2 drugs together Wald DS, et al. Am J Med 2009;122: